USAntibiotics's plant in Tennessee is one of the last plants in the United States that makes amoxicillin, the crucial antibiotic that has been in shortage in some forms since 2022. But the plant isn’t breaking even, financially. WSJ’s Liz Essley Whyte reports on why it is so hard for American-made generic drugs manufacturers to survive.
Further Listening:
- Will Florida’s Plan to Get Cheap Drugs From Canada Work?
- Trillion Dollar Shot
Further Reading:
- Drug Shortages in America Reach a Record High
- Drug Shortages Trigger FTC Probe
Learn more about your ad choices. Visit megaphone.fm/adchoices
Hot, Dry and Booming: A Texas Climate Case Study
Red, White and Who? How Abortion Plays For Trump and Harris
A Fed Insider on the Looming Rate Cut
The Rise of the Tween Shopper
What's Behind the Arrest of the Telegram CEO?
For Kamala Harris, a Big Interview and a Narrow Lead
Private Equity Finally Can Get a Piece of the NFL
Why China Is Risking a Trade War
Lending Elon Musk Money Was A Very Bad Bet
Etsy: Big Commerce or Crafters' Community?
Hope, Unity (and Some Nerves) at the DNC
Outcry at Bank of America Over Dangerous Workloads
The Inside Story of Starbucks’s CEO Drama
At the DNC, Democrats Are Divided Over Gaza
The Economy: Trump vs. Harris
Is the Trump Campaign Going Off Track?
She Was Google’s First Landlord. And She Changed the Internet.
One Man’s Campaign Against DEI
China Is Finally Doing Something About the Fentanyl Crisis
Boeing's Long Flight Delay – in Space
Create your
podcast in
minutes
It is Free
WSJ What’s News
WSJ Your Money Briefing
WSJ Opinion: Potomac Watch
The Daily
Today, Explained